Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

IMPORTANCE: Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE: To evaluat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: George, Saby, Motzer, Robert J., Hammers, Hans J., Redman, Bruce G., Kuzel, Timothy M., Tykodi, Scott S., Plimack, Elizabeth R., Jiang, Joel, Waxman, Ian M., Rini, Brian I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568541/
https://ncbi.nlm.nih.gov/pubmed/27243803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0775
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller